SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus to present EVIDENCES IV clinical trial results of Saroglitazar Magnesium in NAFLD, NASH

23 Oct 2019 Evaluate

Zydus Cadila is going to present the data of its EVIDENCES IV clinical trial of Saroglitazar Magnesium, at The Liver Meeting 2019, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, USA from November 8-12,, 2019.

Earlier Zydus had reported that the EVIDENCES IV clinical trial had achieved the primary end-points in patients with NAFLD and NASH.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

938.90 -1.20 (-0.13%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×